Boehringer and Eli Lilly and Co. are working together to develop a risk model using anonymized patient data. The model will predict how likely patients are to develop three health issues associated with type 2 diabetes: cardiovascular death, kidney failure and hospitalization for heart failure. The goal is to create a model that will help physicians create personalized treatments for patients with type 2. Read more